Stockscreener 앱 받기
3.85
18.26%
-0.86
전일 마감가:
$4.71
열려 있는:
$4.2131
하루 거래량:
5.37M
Relative Volume:
4.57
시가총액:
$73.48M
수익:
-
순이익/손실:
$-40.19M
주가수익비율:
-1.6422
EPS:
-2.3444
순현금흐름:
$-38.49M
1주 성능:
-72.38%
1개월 성능:
-59.77%
6개월 성능:
-51.81%
1년 성능:
-51.63%
1일 변동 폭
$3.66
$4.5499
1주일 범위
$2.66
$14.89
52주 변동 폭
$2.66
$16.00
Elicio Therapeutics Inc Stock (ELTX) Company Profile
명칭
Elicio Therapeutics Inc
전화
(857) 209-0050
주소
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
3.85 | 73.48M | 0 | -40.19M | -38.49M | -2.3444 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Elicio Therapeutics Inc Stock (ELTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-15 | 개시 | Ladenburg Thalmann | Buy |
| 2026-03-10 | 개시 | Rodman & Renshaw | Buy |
Elicio Therapeutics Inc 주식(ELTX)의 최신 뉴스
Elicio Therapeutics (ELTX) Corporate presentation Summary - Quartr
Elicio Therapeutics Inc. (NASDAQ: ELTX) Stock Price, News & Analysis - Kalkine
ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints - Stocktwits
Ladenburg Thalmann starts Elicio Therapeutics stock at buy - Investing.com UK
Ladenburg Thalmann starts Elicio Therapeutics stock at buy By Investing.com - Investing.com Australia
Top Biotech Gainers: QURE Rallies On AMT-130 Update, LNAI On Track, FTH Eyes Q4 Data, ELTX On Watch - RTTNews
Elicio Therapeutics Inc (ELTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Elicio Therapeutics Inc (ELTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Elicio Therapeutics Inc (ELTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Elicio Therapeutics Rebounds as Investors Refocus on Subgroup Data and a Revised Phase 3 Plan - Moomoo
Elicio Therapeutics rebounds as investors refocus on subgroup data and a revised Phase 3 plan - Quiver Quantitative
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Elicio Therapeutics Inc (ELTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Elicio Therapeutics Inc (ELTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Elicio Therapeutics Inc (ELTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Elicio Therapeutics Inc (ELTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Elicio Therapeutics Inc (ELTX) Institutional Confidence - TradingKey
Elicio Therapeutics Inc (ELTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Elicio reports complete responses in metastatic pancreatic cancer - grafa.com
Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug - Benzinga
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment And Subsequent Therapy With Checkpoint Inhibition In Metastatic MKRAS Pancreatic Cancer - marketscreener.com
Elicio Reports Complete Responses in 3 Pancreatic Cancer Patients After ELI-002 7P, Nivolumab Treatment - marketscreener.com
Elicio Therapeutics Announces 100% Complete Responses in Metastatic KRAS Pancreatic Cancer with ELI-002 7P and Checkpoint Inhibitor Therapy 6 – Minichart - Minichart
Elicio Therapeutics stock jumps on pancreatic cancer data By Investing.com - Investing.com Nigeria
Elicio Therapeutics stock jumps on pancreatic cancer data - Investing.com
Elicio reports complete responses in pancreatic cancer patients - Investing.com UK
Elicio reports complete responses in pancreatic cancer patients By Investing.com - Investing.com South Africa
Three complete responses in metastatic PDAC spur new Elicio (NASDAQ: ELTX) trial plan - Stock Titan
Three metastatic pancreatic cancer patients reach rare complete response - Stock Titan
Elicio Therapeutics Investigation Initiated: SueWallSt Investiga - GuruFocus
ELTX Downgraded by Jones Trading -- Rating Change to Hold - GuruFocus
Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX) - TradingView
Levi & Korsinsky Announces Investigation of Securities Claims Against Elicio Therapeutics, Inc. (ELTX) - ACCESS Newswire
H.C. Wainwright Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Elicio Therapeutics shares plunge after pancreatic cancer study misses main goal (ELTX) - MSN
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study - whbl.com
Elicio Confident In Phase III Plan Despite Phase II Miss In Pancreatic Cancer - Citeline News & Insights
Do phase II data Amplify KRAS PDAC promise for Elicio? - BioWorld News
JonesTrading Downgrades Elicio Therapeutics(ELTX.US) to Hold Rating - Moomoo
Top Midday Decliners - Moomoo
H.C. Wainwright reiterates Elicio Therapeutics stock rating at buy - Investing.com UK
ELTX Maintained by HC Wainwright & Co. -- Price Target Raised to $23 - GuruFocus
Elicio Therapeutics reports Phase 2 AMPLIFY-7P results - grafa.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Elicio Therapeutics Pancreatic Cancer Study Disappoints - Benzinga
ELTX INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Elicio Therapeutics, Inc. - GlobeNewswire
H.C. Wainwright reiterates Elicio Therapeutics stock rating at buy By Investing.com - Investing.com Australia
Elicio nosedives on phase 2 data for pancreatic cancer asset (ELTX:NASDAQ) - Seeking Alpha
Elicio crashes on Phase II miss for cancer vaccine, pins hopes on post-hoc signal - FirstWord PHARMA
Elicio Thera tanks on disappointing Phase II AMPLIFY-7P study - The Pharma Letter
Rodman & Renshaw raises Elicio Therapeutics price target to $17.50 By Investing.com - Investing.com Canada
Elicio Therapeutics Inc (ELTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):